$ELTX
Elicio Therapeutics, Inc. Stock $eltx

$eltx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000160148524000023 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$3.235M	$11.90M
YoY Change		-13.62%	-18.73%
% of Gross Profit
Research & Development	$7.559M	$6.157M	$23.85M
YoY Change	2218.71%	3748.13%	31.76%
% of Gross Profit
Depreciation & Amortization	$100.0K	$82.00K	$382.0K
YoY Change	354.55%	164.52%	91.0%
% of Gross Profit
Operating Expenses	$7.559M	$9.392M	$35.75M
YoY Change	2218.71%	140.51%	97.49%
Operating Profit	-$10.24M		-$35.75M
YoY Change	122.29%		-9.78%
Interest Expense	$36.00K	$322.0K	-$53.00K
YoY Change	-90.58%	-46.86%	-107.37%
% of Operating Profit
Other Income/Expense, Net	-$1.586M	$15.00K	-$2.000K
YoY Change	-2365.71%	200.0%	-100.25%
Pretax Income		-$8.949M	-$35.20M
YoY Change		38.96%	-9.29%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.83M	-$8.949M	-$35.20M
YoY Change	160.68%	38.96%	-9.31%
Net Earnings / Revenue
Basic Earnings Per Share	-$1.15		-$6.96
Diluted Earnings Per Share	-$1.15	-$1.77	-$6.96
COMMON SHARES
Basic Shares Outstanding	10.24M shares	8.407M shares	5.056M shares
Diluted Shares Outstanding	10.27M shares		5.056M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.85M	$12.89M	$12.89M
YoY Change	-59.43%	-74.46%	-74.46%
Cash & Equivalents	$11.90M	$12.89M	$12.89M
Short-Term Investments
Other Short-Term Assets	$2.164M	$3.281M	$3.281M
YoY Change	434.32%	1233.74%	247.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.13M	$16.35M	$16.35M
YoY Change	-65.22%	-68.21%	-68.21%
LONG-TERM ASSETS
Property, Plant & Equipment	$635.0K	$7.280M	$7.280M
YoY Change		2566.67%	1612.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$3.361M	$3.518M	$3.518M
YoY Change	289.0%	5667.21%	5667.21%
Total Long-Term Assets	$10.35M	$10.80M	$10.80M
YoY Change	807.89%	693.97%	693.97%
TOTAL ASSETS
Total Short-Term Assets	$14.13M	$16.35M	$16.35M
Total Long-Term Assets	$10.35M	$10.80M	$10.80M
Total Assets	$24.48M	$27.15M	$27.15M
YoY Change	-41.39%	-48.58%	-48.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.105M	$4.369M	$4.369M
YoY Change	59.68%	60.63%	60.63%
Accrued Expenses	$3.324M	$4.667M	$4.667M
YoY Change	201.36%	81.67%	134.4%
Deferred Revenue	$600.0K	$694.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.951M	$9.766M	$9.766M
YoY Change	193.01%	53.34%	53.34%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$13.66M	$6.007M	$6.007M
YoY Change	19412.86%	142.12%	142.12%
Total Long-Term Liabilities	$13.66M	$6.007M	$6.007M
YoY Change	19412.86%	126.76%	126.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.951M	$9.766M	$9.766M
Total Long-Term Liabilities	$13.66M	$6.007M	$6.007M
Total Liabilities	$19.61M	$15.77M	$15.77M
YoY Change	833.37%	74.91%	74.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$154.0M	-$142.2M
YoY Change	-40.43%	-43.99%
Common Stock	$102.0K	$96.00K
YoY Change	-66.11%	-68.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.870M	$11.37M	$11.37M
YoY Change
Total Liabilities & Shareholders Equity	$24.48M	$27.15M	$27.15M
YoY Change	-41.39%	-48.58%	-48.58%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$11.83M	-$8.949M	-$35.20M
YoY Change	160.68%	38.96%	-9.31%
Depreciation, Depletion And Amortization	$100.0K	$82.00K	$382.0K
YoY Change	354.55%	164.52%	91.0%
Cash From Operating Activities	-$12.12M	-$9.894M	-$32.69M
YoY Change	50.04%	123.54%	-14.84%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$4.000K	$66.00K
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$3.000K	$4.000K	$34.00K
YoY Change	-100.03%
Cash From Investing Activities	$3.000K	-$2.000K	-$32.00K
YoY Change	-100.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.976M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$11.02M	7.003M	38.61M
YoY Change	-437.33%	-46786.67%	-64455.0%
NET CHANGE
Cash From Operating Activities	-$12.12M	-9.894M	-32.69M
Cash From Investing Activities	$3.000K	-2.000K	-32.00K
Cash From Financing Activities	$11.02M	7.003M	38.61M
Net Change In Cash	-$1.095M	-2.893M	5.887M
YoY Change	-94.85%	-34.86%	-115.38%
FREE CASH FLOW
Cash From Operating Activities	-$12.12M	-$9.894M	-$32.69M
Capital Expenditures	$0.00	-$4.000K	$66.00K
Free Cash Flow	-$12.12M	-$9.890M	-$32.76M
YoY Change	49.73%	123.45%	-14.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39990
CY2023	dei	Entity Registrant Name EntityRegistrantName	Elicio Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-3430072
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	451 D Street, 5th Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02210
CY2023	dei	City Area Code CityAreaCode	857
CY2023	dei	Local Phone Number LocalPhoneNumber	209-0050
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12894000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2732000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	16348000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	717000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6563000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4369000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3757000	usd
CY2023Q4	angn	Warrant Liability Current WarrantLiabilityCurrent	11000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9766000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6007000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	15773000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	373000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	65000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	429000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-945000	usd
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001601485
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	47100000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10235469	shares
CY2023	dei	Auditor Name AuditorName	Baker Tilly US, LLP
CY2023	dei	Auditor Location AuditorLocation	Tewksbury, Massachusetts
CY2023	dei	Auditor Firm AuditorFirmId	23
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6156000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	722000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	1641000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2920000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10717000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1147000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7350000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	685000	usd
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	617000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2833000	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2833000	usd
CY2023Q4	us-gaap	Assets Assets	27146000	usd
CY2022Q4	us-gaap	Assets Assets	22664000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2805000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1935000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	694000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1436000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	910000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	692000	usd
CY2023Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	25000	usd
CY2022Q4	us-gaap	Deferred Compensation Share Based Arrangements Liability Current DeferredCompensationShareBasedArrangementsLiabilityCurrent	0	usd
CY2022Q4	angn	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6868000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6789000	usd
CY2023Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	0	usd
CY2022Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent	92000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13749000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	111060000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9618178	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	320281	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9603723	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	320281	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	96000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3000	usd
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	14455	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	150000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	153827000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	4860000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-197000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142203000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107008000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11373000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102145000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	27146000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22664000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23849000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18103000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11896000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5630000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	35745000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	23733000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-35745000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-23733000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	605000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	204000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1059000	usd
CY2022	us-gaap	Interest Expense InterestExpense	3597000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4475000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35392000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.96
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.96
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-89.27
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5056225	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5056225	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	315998	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315998	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102145000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	127000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	67000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2400000	usd
CY2023	angn	Stock Issued During Period Value Reverse Recapitalization StockIssuedDuringPeriodValueReverseRecapitalization	19526000	usd
CY2023	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	150000	usd
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	6999000	usd
CY2023	angn	Stock Issued During Period Value Service Agreement StockIssuedDuringPeriodValueServiceAgreement	75000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1179000	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-197000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35195000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	11373000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-74536000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	579000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	13000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1200000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28208000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102145000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35195000	usd
CY2023	us-gaap	Depreciation Depreciation	382000	usd
CY2022	us-gaap	Depreciation Depreciation	390000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	788000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	667000	usd
CY2023	angn	Interest Expense Noncash InterestExpenseNoncash	1061000	usd
CY2022	angn	Interest Expense Noncash InterestExpenseNoncash	3596000	usd
CY2023	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	429000	usd
CY2022	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-945000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1179000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	579000	usd
CY2023	angn	Professional Services Expense Noncash ProfessionalServicesExpenseNoncash	75000	usd
CY2022	angn	Professional Services Expense Noncash ProfessionalServicesExpenseNoncash	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	605000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	2000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-105000	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-4000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	729000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1985000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-114000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	23000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1125000	usd
CY2023	angn	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	2216000	usd
CY2022	angn	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	-305000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-742000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1436000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-825000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-535000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-32694000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22179000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	654000	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	34000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-654000	usd
CY2023	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	24001000	usd
CY2022	us-gaap	Cash Acquired In Excess Of Payments To Acquire Business CashAcquiredInExcessOfPaymentsToAcquireBusiness	0	usd
CY2023	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	2364000	usd
CY2022	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	10000000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	21120000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6999000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	150000	usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	127000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	82000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38613000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21202000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	5887000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1631000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8414000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10045000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14301000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8414000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12894000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6156000	usd
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1407000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2258000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14301000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8414000	usd
CY2023	angn	Gain Loss On Disposal Of Property And Equipment Noncash GainLossOnDisposalOfPropertyAndEquipmentNoncash	105000	usd
CY2022	angn	Gain Loss On Disposal Of Property And Equipment Noncash GainLossOnDisposalOfPropertyAndEquipmentNoncash	4000	usd
CY2023	angn	Settlement Of Promissory Notes Payable SettlementOfPromissoryNotesPayable	10027000	usd
CY2022	angn	Settlement Of Promissory Notes Payable SettlementOfPromissoryNotesPayable	0	usd
CY2023	angn	Accretion Of Promissory Note Discount From Embedded Derivative AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative	130000	usd
CY2022	angn	Accretion Of Promissory Note Discount From Embedded Derivative AccretionOfPromissoryNoteDiscountFromEmbeddedDerivative	0	usd
CY2023	angn	Accretion Of Promissory Note To Face Value AccretionOfPromissoryNoteToFaceValue	897000	usd
CY2022	angn	Accretion Of Promissory Note To Face Value AccretionOfPromissoryNoteToFaceValue	0	usd
CY2023	angn	Vesting Of Restricted Common Stock Noncash VestingOfRestrictedCommonStockNoncash	67000	usd
CY2022	angn	Vesting Of Restricted Common Stock Noncash VestingOfRestrictedCommonStockNoncash	13000	usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	111060000	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	usd
CY2023	angn	Accretion Of Convertible Notes Discount From Embedded Derivative AccretionOfConvertibleNotesDiscountFromEmbeddedDerivative	0	usd
CY2022	angn	Accretion Of Convertible Notes Discount From Embedded Derivative AccretionOfConvertibleNotesDiscountFromEmbeddedDerivative	2344000	usd
CY2023	angn	Accretion Of Convertible Notes Discount From Issuance Costs AccretionOfConvertibleNotesDiscountFromIssuanceCosts	0	usd
CY2022	angn	Accretion Of Convertible Notes Discount From Issuance Costs AccretionOfConvertibleNotesDiscountFromIssuanceCosts	328000	usd
CY2023	angn	Interest Expense From Convertible Notes Payable InterestExpenseFromConvertibleNotesPayable	0	usd
CY2022	angn	Interest Expense From Convertible Notes Payable InterestExpenseFromConvertibleNotesPayable	923000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9700000	shares
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-142200000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12900000	usd
CY2023Q2	angn	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.0181
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	operating_segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Use of Estimates</span></div>The Company’s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the operating right of use assets and operating lease liability, and going concern.
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div>Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.06
CY2023Q2	angn	Number Of Members Of The Board Of Directors NumberOfMembersOfTheBoardOfDirectors	9	board_member
CY2023Q2	angn	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.0181
CY2023Q2	angn	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.0181
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8387025	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8387025	shares
CY2023Q2	angn	Cash And Cash Equivalents Acquired Through Reverse Recapitalization CashAndCashEquivalentsAcquiredThroughReverseRecapitalization	24001000	usd
CY2023Q2	angn	Other Current Assets Acquired Through Reverse Recapitalization OtherCurrentAssetsAcquiredThroughReverseRecapitalization	540000	usd
CY2023Q2	angn	Promissory Notes Acquired Through Reverse Recapitalization PromissoryNotesAcquiredThroughReverseRecapitalization	10027000	usd
CY2023Q2	angn	Accrued Liabilities Assumed Through Reverse Recapitalization AccruedLiabilitiesAssumedThroughReverseRecapitalization	2438000	usd
CY2023Q2	angn	Net Assets Acquired Through Reverse Recapitalization NetAssetsAcquiredThroughReverseRecapitalization	32130000	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	600000	usd
CY2023	angn	Reverse Recapitalization Transaction Costs ReverseRecapitalizationTransactionCosts	2900000	usd
CY2023Q4	angn	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	1883000	usd
CY2022Q4	angn	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	2132000	usd
CY2023Q4	angn	Advanced Professional Fees AdvancedProfessionalFees	300000	usd
CY2022Q4	angn	Advanced Professional Fees AdvancedProfessionalFees	648000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	376000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	104000	usd
CY2023Q4	angn	Other Prepaid Expenses And Other Assets Current OtherPrepaidExpensesAndOtherAssetsCurrent	173000	usd
CY2022Q4	angn	Other Prepaid Expenses And Other Assets Current OtherPrepaidExpensesAndOtherAssetsCurrent	36000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2732000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2920000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1948000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2270000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1231000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1123000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	717000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1147000	usd
CY2023	us-gaap	Depreciation Depreciation	400000	usd
CY2022	us-gaap	Depreciation Depreciation	400000	usd
CY2022Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2800000	usd
CY2023Q4	us-gaap	Prepaid Expense Other Noncurrent PrepaidExpenseOtherNoncurrent	2800000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	945000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	180000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1849000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1491000	usd
CY2023Q4	angn	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	912000	usd
CY2022Q4	angn	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	260000	usd
CY2023Q4	angn	Accrued Other Operating Liabilities Current AccruedOtherOperatingLiabilitiesCurrent	51000	usd
CY2022Q4	angn	Accrued Other Operating Liabilities Current AccruedOtherOperatingLiabilitiesCurrent	4000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3757000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1935000	usd
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	700000	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	angn	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.0181
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	6948560	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	4997920	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	4997920	shares
CY2023Q2	angn	Recapitalization Exchange Ratio RecapitalizationExchangeRatio	0.0181
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	854076	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.24
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M19D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	219672	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.68
CY2023	angn	Share Based Compensation Arrangement By Share Based Payment Award Options Options In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsInPeriod	351656	shares
CY2023	angn	Share Based Compensation Arrangements By Share Based Payment Award Options Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOptionsOutstandingWeightedAverageExercisePrice	61.99
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	16349	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	7.74
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	103131	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.83
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1305924	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	21.27
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M4D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2510341000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	871564	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	41.91
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	860479000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	219672	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.68
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2400000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1179000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	579000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	144814	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	53.59
CY2022Q4	angn	Class Of Warrant Or Right Weighted Average Life ClassOfWarrantOrRightWeightedAverageLife	P6Y6M
CY2023	angn	Class Of Warrant Or Right Assumed In Acquisition ClassOfWarrantOrRightAssumedInAcquisition	3950	shares
CY2023	angn	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Warrants Assumed In Acquisition ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsWarrantsAssumedInAcquisition	76.00
CY2023	angn	Call Of Warrant Or Right Weighted Average Life Warrants Assumed In Acquisition CallOfWarrantOrRightWeightedAverageLifeWarrantsAssumedInAcquisition	P4Y8M12D
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	148764	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	54.19
CY2023Q4	angn	Class Of Warrant Or Right Weighted Average Life ClassOfWarrantOrRightWeightedAverageLife	P5Y6M
CY2023	angn	Operating Lease Future Minimum Annual Maintenance Payments OperatingLeaseFutureMinimumAnnualMaintenancePayments	100000	usd
CY2023	angn	Operating Lease Future Minimum Annual Maintenance Payments Due Thereafter OperatingLeaseFutureMinimumAnnualMaintenancePaymentsDueThereafter	100000	usd
CY2023Q2	us-gaap	Proceeds From Secured Lines Of Credit ProceedsFromSecuredLinesOfCredit	700000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1500000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1200000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1380000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1106000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	8017000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.075
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1427000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1350000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1383000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1425000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1467000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1765000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8817000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1900000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6917000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	910000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6007000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	7743000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	5162000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	3116000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	2102000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-10859000	usd
CY2022	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-7264000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.051
CY2023	angn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.003
CY2022	angn	Effective Income Tax Rate Reconciliation Permanent Differences Percent EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent	-0.046
CY2023	angn	Effective Income Tax Rate Reconciliation Tax Credit Federal Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent	0.031
CY2022	angn	Effective Income Tax Rate Reconciliation Tax Credit Federal Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditFederalResearchAndDevelopmentPercent	0.026
CY2023	angn	Effective Income Tax Rate Reconciliation Tax Credit State Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent	0.008
CY2022	angn	Effective Income Tax Rate Reconciliation Tax Credit State Research And Development Percent EffectiveIncomeTaxRateReconciliationTaxCreditStateResearchAndDevelopmentPercent	0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.309
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.259
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60696000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19146000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12940000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3820000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	13686000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4304000	usd
CY2023Q4	angn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1897000	usd
CY2022Q4	angn	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	1949000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2732000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	611000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1800000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1915000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	33000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	37000	usd
CY2023Q4	angn	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	90118000	usd
CY2022Q4	angn	Deferred Tax Assets Net Before Valuation Allowance DeferredTaxAssetsNetBeforeValuationAllowance	27878000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	90118000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27878000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023Q2	angn	Reverse Recapitalization Deferred Tax Assets Acquired Net ReverseRecapitalizationDeferredTaxAssetsAcquiredNet	50100000	usd
CY2023Q2	angn	Reverse Recapitalization Deferred Tax Assets Valuation Allowance ReverseRecapitalizationDeferredTaxAssetsValuationAllowance	50100000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	62200000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4100000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35195000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-28208000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5056225	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5056225	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	315998	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	315998	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-89.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-89.27
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1456621	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6004050	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001601485-24-000023-index-headers.html	Edgar Link	pending
0001601485-24-000023-index.html	Edgar Link	pending
0001601485-24-000023.txt	Edgar Link	pending
0001601485-24-000023-xbrl.zip	Edgar Link	pending
angn-20231231.htm	Edgar Link	pending
angn-20231231.xsd	Edgar Link	pending
angn-20231231_g1.jpg	Edgar Link	pending
angn-20231231_g2.jpg	Edgar Link	pending
angn-20231231_g3.jpg	Edgar Link	pending
btconsent10-k.htm	Edgar Link	pending
btconsent10-k001.jpg	Edgar Link	pending
elicio-amendedandrestate.htm	Edgar Link	pending
elicio-amendedandrestate001.jpg	Edgar Link	pending
elicio-amendedandrestate002.jpg	Edgar Link	pending
elicio-amendedandrestate003.jpg	Edgar Link	pending
elicio-executiveseveranc.htm	Edgar Link	pending
elicio-executiveseveranc001.jpg	Edgar Link	pending
elicio-executiveseveranc002.jpg	Edgar Link	pending
elicio-executiveseveranc003.jpg	Edgar Link	pending
elicio-executiveseveranc004.jpg	Edgar Link	pending
elicio-executiveseveranc005.jpg	Edgar Link	pending
elicio-executiveseveranc006.jpg	Edgar Link	pending
elicio-executiveseveranc007.jpg	Edgar Link	pending
elicio-executiveseveranc008.jpg	Edgar Link	pending
elicio-executiveseveranc009.jpg	Edgar Link	pending
elicio-executiveseveranc010.jpg	Edgar Link	pending
elicio-executiveseveranc011.jpg	Edgar Link	pending
elicio-executiveseveranc012.jpg	Edgar Link	pending
elicio-executiveseveranc013.jpg	Edgar Link	pending
elicio-executiveseveranc014.jpg	Edgar Link	pending
elicio-formofinducements.htm	Edgar Link	pending
elicio-formofinducements001.jpg	Edgar Link	pending
elicio-formofinducements002.jpg	Edgar Link	pending
elicio-formofinducements003.jpg	Edgar Link	pending
angn-20231231_cal.xml	Edgar Link	unprocessable
angn-20231231_def.xml	Edgar Link	unprocessable
angn-20231231_lab.xml	Edgar Link	unprocessable
angn-20231231_pre.xml	Edgar Link	unprocessable
angn-20231231_htm.xml	Edgar Link	completed
elicio-formofinducements004.jpg	Edgar Link	pending
elicio-formofinducements005.jpg	Edgar Link	pending
elicio-formofinducements006.jpg	Edgar Link	pending
elicio-formofinducements007.jpg	Edgar Link	pending
elicio-formofinducements008.jpg	Edgar Link	pending
elicio-formofinducements009.jpg	Edgar Link	pending
elicio-formofinducements010.jpg	Edgar Link	pending
elicio-formofinducements011.jpg	Edgar Link	pending
elicio-formofinducements012.jpg	Edgar Link	pending
elicio-formofinducements013.jpg	Edgar Link	pending
elicio-formofoptionagree.htm	Edgar Link	pending
elicio-formofoptionagree001.jpg	Edgar Link	pending
elicio-formofoptionagree002.jpg	Edgar Link	pending
elicio-formofoptionagree003.jpg	Edgar Link	pending
elicio-formofoptionagree004.jpg	Edgar Link	pending
elicio-formofoptionagree005.jpg	Edgar Link	pending
elicio-formofoptionagree006.jpg	Edgar Link	pending
elicio-formofoptionagree007.jpg	Edgar Link	pending
elicio-formofoptionagree008.jpg	Edgar Link	pending
elicio-formofoptionagree009.jpg	Edgar Link	pending
elicio-formofoptionagree010.jpg	Edgar Link	pending
elicio-inducementincenti.htm	Edgar Link	pending
elicio-inducementincenti001.jpg	Edgar Link	pending
elicio-inducementincenti002.jpg	Edgar Link	pending
elicio-inducementincenti003.jpg	Edgar Link	pending
elicio-inducementincenti004.jpg	Edgar Link	pending
elicio-inducementincenti005.jpg	Edgar Link	pending
elicio-inducementincenti006.jpg	Edgar Link	pending
elicio-inducementincenti007.jpg	Edgar Link	pending
elicio-inducementincenti008.jpg	Edgar Link	pending
elicio-inducementincenti009.jpg	Edgar Link	pending
elicio-inducementincenti010.jpg	Edgar Link	pending
elicio-inducementincenti011.jpg	Edgar Link	pending
elicio-inducementincenti012.jpg	Edgar Link	pending
elicio-inducementincenti013.jpg	Edgar Link	pending
elicio-inducementincenti014.jpg	Edgar Link	pending
elicio-inducementincenti015.jpg	Edgar Link	pending
elicio-inducementincenti016.jpg	Edgar Link	pending
elicio-inducementincenti017.jpg	Edgar Link	pending
elicio-inducementincenti018.jpg	Edgar Link	pending
elicio-inducementincenti019.jpg	Edgar Link	pending
elicio-inducementincenti020.jpg	Edgar Link	pending
elicio-inducementincenti021.jpg	Edgar Link	pending
elicio-powerofattorney.htm	Edgar Link	pending
elicio-powerofattorney001.jpg	Edgar Link	pending
elicio-powerofattorney002.jpg	Edgar Link	pending
elicio_clawbackpolicynas.htm	Edgar Link	pending
elicio_clawbackpolicynas001.jpg	Edgar Link	pending
elicio_clawbackpolicynas002.jpg	Edgar Link	pending
elicio_clawbackpolicynas003.jpg	Edgar Link	pending
ex311_eltx-12312023x10xk.htm	Edgar Link	pending
ex311_eltx-12312023x10xk001.jpg	Edgar Link	pending
ex311_eltx-12312023x10xk002.jpg	Edgar Link	pending
ex312_eltx-12312023x10xk.htm	Edgar Link	pending
ex312_eltx-12312023x10xk001.jpg	Edgar Link	pending
ex312_eltx-12312023x10xk002.jpg	Edgar Link	pending
ex321_eltx-12312023x10xk.htm	Edgar Link	pending
ex321_eltx-12312023x10xk001.jpg	Edgar Link	pending
ex322_eltx-12312023x10xk.htm	Edgar Link	pending
ex322_eltx-12312023x10xk001.jpg	Edgar Link	pending
exhibit211.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ELTX
Elicio Therapeutics, Inc. Stock $eltx

2024 Q1 Form 10-K Financial Statement

#000160148524000023 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTX Elicio Therapeutics, Inc. Stock $eltx

2024 Q1 Form 10-K Financial Statement

#000160148524000023 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ELTX
Elicio Therapeutics, Inc. Stock $eltx